CMV stands for Cytomegalovirus. It's a common virus that can cause infections in people of all ages. It can affect different parts of the body, like the lungs, brain, or digestive system. Sometimes it's passed from mother to baby during pregnancy or birth, causing problems for the baby.
Every report comes from a Lived member, sent anonymously.
Have you tried Valganciclovir for CMV?
Cytomegalovirus (CMV) is a very common virus, related to the viruses that cause chickenpox and mononucleosis (mono). In the United States, more than half of adults have been infected by age 40. Most never feel sick or know they have it. When it does cause symptoms in a healthy person, they usually resemble a mild mono-like illness: fever, sore throat, tiredness and swollen glands. After the first infection, CMV stays in the body for life in an inactive state. That is rarely a problem for someone with a healthy immune system. CMV matters most in two situations. A baby infected before birth (congenital CMV) can develop hearing loss or other lasting problems. And in people whose immune systems are weakened, such as after an organ or stem cell transplant or with advanced HIV (human immunodeficiency virus), the virus can become active and damage the eyes, lungs, liver or digestive tract.
CMV spreads through close contact with body fluids, including saliva, urine, blood, tears, semen and breast milk. It can also pass through sexual contact, organ transplants and blood transfusions. The virus spreads easily among young children, including in daycare, so parents of toddlers and childcare workers are commonly exposed. A pregnant person who catches CMV can pass it to the baby. When it is a first infection during the first or second trimester, the virus reaches the baby in roughly 30 to 40% of cases. Reducing contact with young children's saliva and urine lowers the risk: not sharing food, utensils, cups or pacifiers, and washing hands with soap and water after changing diapers or wiping a child's nose or mouth. Serious CMV disease in adults depends mainly on how well the immune system can keep the virus in check. After an organ transplant, risk is highest when the donor has had CMV and the recipient has not. After a stem cell transplant, risk is highest when the recipient already carries CMV, because the virus can reactivate before the new immune system is working. Risk is also high in people with advanced HIV or other treatments that strongly suppress the immune system.
Because CMV is so common and usually silent, healthy people are rarely tested. A blood test for CMV antibodies (proteins the immune system makes against the virus) shows whether someone has ever been infected, which is useful before a transplant. Routine CMV screening in pregnancy is not recommended in the United States. In newborns, congenital CMV is confirmed by testing saliva or urine for the virus's genetic material, usually with a saliva test confirmed by a urine test. This must happen within 2 to 3 weeks after birth, because babies can also pick up CMV after birth, which is usually harmless for full-term babies, and later tests cannot tell the two apart. Antibody tests cannot diagnose congenital CMV. In people with weakened immune systems, clinicians measure the amount of virus in the blood and, depending on symptoms, may examine the eyes or take a tissue sample from the lung, colon or another affected organ.
Most healthy people with CMV need no treatment, because the immune system controls the infection on its own. For babies with signs of congenital CMV at birth, specialists often recommend antiviral treatment, usually valganciclovir (Valcyte), an oral antiviral, sometimes started as intravenous ganciclovir. In a large trial, six months of valganciclovir, compared with six weeks, modestly improved hearing and language development over two years. Treatment does not undo damage already present, and decisions about babies without symptoms are less settled. For transplant recipients, the main goal is prevention. Teams either give a preventive antiviral for several months after the transplant, such as valganciclovir or letermovir (Prevymis), or check the blood regularly for the virus and start treatment if it appears. When CMV does cause disease, valganciclovir or ganciclovir are the usual first treatments. Other antivirals, including maribavir (Livtencity), are used when the virus does not respond. For people with HIV, effective HIV treatment that rebuilds the immune system is central to preventing and controlling CMV. Valganciclovir and ganciclovir can lower white blood cell, red blood cell and platelet counts, so people taking them have regular blood count checks.
For most healthy people, CMV passes unnoticed or after a few weeks of mono-like tiredness, and it does not need follow-up. Most babies born with CMV never have health problems from it. About 1 in 5 do develop lasting problems, most often hearing loss, and less often developmental delay, vision problems or seizures. Babies with signs at birth are the most likely to be affected. Hearing loss can appear or worsen during the first years of life even after a normal newborn hearing test, so children with congenital CMV have repeated hearing checks. Finding hearing loss early allows hearing aids, speech support and other services to start while they help most. For transplant recipients and others with weakened immune systems, CMV is often a matter of monitoring rather than illness. Prevention usually lasts for a set period, but CMV can still appear in the months after preventive medicine stops, which is why blood tests often continue for a while afterward. When disease does occur, treatment often lasts weeks and requires close follow-up.
Talk with a prenatal care provider if you have a flu-like or mono-like illness during pregnancy, or if you are concerned about exposure through young children. If your newborn does not pass the hearing screen or your provider suspected CMV in pregnancy, ask about CMV testing right away, within the first 2 to 3 weeks. If you have a transplant, advanced HIV or another cause of a weakened immune system, contact your care team promptly about fever, diarrhea, painful swallowing or new breathing problems. New floaters, blind spots or blurred vision need an eye examination the same day, because CMV infection of the retina (the light-sensing layer at the back of the eye) can cause permanent vision loss if it is not treated quickly.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with CMV is like, what's helped you, or ask the community a question.